The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Official Title: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Study ID: NCT05271630
Brief Summary: The purpose of the study is to determine outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post Autologous Stem Cell Transplant (ASCT).
Detailed Description: This non-interventional, cohort prospective research study will assess outcomes for Multiple Myeloma patients on maintenance single agent vs. doublet (IMiD + PI) combination chemotherapy post ASCT.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Moffitt Cancer Center, Tampa, Florida, United States
Name: Doris Hansen, MD
Affiliation: Moffitt Cancer Center
Role: PRINCIPAL_INVESTIGATOR